Could Gene Therapy Someday Eliminate HIV?U.S. News & World ReportWEDNESDAY, Jan. 3, 2018 (HealthDay News) — Gene therapy may have the potential to eradicate HIV in people infected with the virus, new animal research suggests. The science centers aroun… Continue reading
|
Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide
Benzinga … 9 percent to $12.14 after the company reported the termination of its merger deal with China’s Ant Financial, due to the CFIUS rejected the companies proposals related to protecting personal data. Shares of Atara Biotherapeutics Inc (NASDAQ: ATRA … |
Investor’s Business Daily |
Spark Therapeutics Prices First-Ever Gene Therapy At $850,000 …
Investor’s Business Daily Spark and GlaxoSmithKline are pricing the world’s first approved gene therapies at prices approaching $1 million. |
FiercePharma |
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
Nasdaq Shares of Inovio Pharmaceuticals, Inc. INO ) have gained about 13.32%, after the company announced that it has entered into an amended agreement with Chinese partner – ApolloBio Corporation. Per the amended agreement, ApolloBio will have the exclusive … Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBioFiercePharma Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider Could Inovio Pharmaceuticals, Inc. (INO) Rise Even More? The Stock Had Another Big Increase TodayFrisco Fastball Market Exclusive all 50 news articles » |
Ovarian Cancer News Today |
Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer
Ovarian Cancer News Today Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, which are boosted to fight the tumor by exposure to tumor proteins. The … |
|
IDbyDNA, Locus Biosciences Partner on CDx for CRISPR …
GenomeWeb The next-generation sequencing test will be used to select patients for a clinical trial of Locus’ Pseudomonas aeruginosa antimicrobial product. Locus Biosciences and IDbyDNA Partner to Develop Companion …PR Newswire (press release) |